A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma - Regional Cancer Care Associates LLC

Clinical Trials

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary
Locations
Freehold
Sparta
Sponsor
Protocol Number
Genentech WO29637 Renal Cell
Cancer Diagnosis
Renal Cancer
To Learn More Call
201-510-0910